Potentiation of Azole Antifungals by 2-Adamantanamine
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Azoles are among the most successful classes of antifungals. They act by inhibiting α-14 lanosterol demethylase in the ergosterol biosynthesis pathway. Oropharyngeal candidiasis (OPC) occurs in about 90% of HIV-infected individuals, and 4 to 5% are refractory to current therapies, including azoles, due to the formation of resistant biofilms produced in the course of OPC. We reasoned that compounds affecting a different target may potentiate azoles to produce increased killing and an antibiofilm therapeutic. 2-Adamantanamine (AC17) was identified in a screen for compounds potentiating the action of miconazole against biofilms of Candida albicans . AC17, a close structural analog to the antiviral amantadine, did not affect the viability of C. albicans but caused the normally fungistatic azoles to become fungicidal. Transcriptome analysis of cells treated with AC17 revealed that the ergosterol and filamentation pathways were affected. Indeed, cells exposed to AC17 had decreased ergosterol contents and were unable to invade agar. In vivo , the combination of AC17 and fluconazole produced a significant reduction in fungal tissue burden in a guinea pig model of cutaneous candidiasis, while each treatment alone did not have a significant effect. The combination of fluconazole and AC17 also showed improved efficacy ( P value of 0.018) compared to fluconazole alone when fungal lesions were evaluated. AC17 is a promising lead in the search for more effective antifungal therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Growth of Candida albicans hyphae
Sudbery, P. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2636 · Cited by 1,110 · cited 1×
“albicans to form hyphae is an important virulence factor required for pathogenesis and invasion into tissues (26).”
BackgroundAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362 · cited 1×
“Synergy between cyclosporine or radicicol and the azoles occurs through inhibition of calcineurin, but AC17 did not inhibit calcineurin according to a UTR2lacZ reporter construct (data not shown) (22).”
BackgroundOnyewu, C., Blankenship, J. R., Del Poeta, M., & Heitman, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.956-964.2003 · Cited by 282
Patients with Long-Term Oral Carriage Harbor High-Persister Mutants of Candida albicans
LaFleur, M. D., Qi, Q., & Lewis, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00860-09 · Cited by 237
Self-citationEpidemiology of Candida albicans Infections and Role of Non-Candidaalbicans Yeasts
Ruhnke, M. (2006) · Current Drug Targets · doi:10.2174/138945006776359421 · Cited by 210
Genetic Architecture of Hsp90-Dependent Drug Resistance
Cowen, L. E., Carpenter, A. E., Matangkasombut, O., Fink, G. R., & Lindquist, S. (2006) · Eukaryotic Cell · doi:10.1128/ec.00274-06 · Cited by 159
Prasad, T., Chandra, A., Mukhopadhyay, C. K., & Prasad, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00653-06 · Cited by 149
Fiori, A., & Van Dijck, P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06017-11 · Cited by 112 · cited 1×
“Synergy with doxycycline occurred at high concentrations, which are unlikely to be clinically achievable, and was due to iron chelation (29).”
Background
Cited by
Antifungal Peptides as Therapeutic Agents
Fernández de Ullivarri, M., Arbulu, S., Garcia-Gutierrez, E., & Cotter, P. D. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00105 · Cited by 264
Targeting Efflux Pumps to Overcome Antifungal Drug Resistance
Holmes, A. R., Cardno, T. S., Strouse, J. J., Ivnitski-Steele, I., Keniya, M. V., Lackovic, K., Monk, B. C., Sklar, L. A., & Cannon, R. D. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0050 · Cited by 156
De Cremer, K., Lanckacker, E., Cools, T. L., Bax, M., De Brucker, K., Cos, P., Cammue, B. P. A., & Thevissen, K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04229-14 · Cited by 77
Feng, Y., Lu, H., Whiteway, M., & Jiang, Y. (2023) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2023.10.019 · Cited by 40
Caldara, M., & Marmiroli, N. (2020) · Microorganisms · doi:10.3390/microorganisms8050742 · Cited by 8
Metadata
- Authors
- LaFleur, M. D., Sun, L., Lister, I., Keating, J., Nantel, A., Long, L., Ghannoum, M., North, J., Lee, R. E., Coleman, K., Dahl, T., & Lewis, K.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-08
- Volume
- 57
- Issue
- 8
- Pages
- 3585-3592
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1998699419
- Cited by
- 35
- References
- 13
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentiation of Azole Antifungals by 2-Adamantanamine. https://app.cochat.ai/papers/10.1128/aac.00294-13
- The paper
- LaFleur, M. D., Sun, L., Lister, I., Keating, J., Nantel, A., Long, L., Ghannoum, M., North, J., Lee, R. E., Coleman, K., Dahl, T., & Lewis, K. (2013). Potentiation of Azole Antifungals by 2-Adamantanamine. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00294-13
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.